The Recall Desk

Hazard

Allergen Penicillin recalls

106 recalls in our database tag this hazard, drawn from FDA, USDA FSIS, CPSC, and NHTSA source notices.

What the numbers show

Total
106
Critical
0
Severe
38
Most recent
2016-01-20

Of the 106 allergen penicillin recalls we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 38 (36%) are Severe.

About this hazard tag

Hazard tags are short, machine-readable labels we attach to every recall to make cross-cutting queries possible — “all allergen penicillin recalls regardless of agency”, “all listeria recalls in California”, “all airbag recalls in 2025”. The tags are extracted from each recall’s source text during the LLM rewrite step and validated against a fixed schema.

A recall can carry multiple tags — a Listeria recall might also be tagged ready-to-eat and undeclared-allergen. Use the full-text search if you want to combine hazard tags with brand or category filters.

26–50 of 106

  • SevereFDA (Drugs)·D-949-2015·2015-04-29

    Vancomycin HCl Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Vancomycin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Vancomycin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-924-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tetracycline HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tetracycline HCl active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tetracycline HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-805-2015·2015-04-29

    Attix Pharmaceuticals Recalls Mometasone Furoate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Mometasone Furoate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Mometasone Furoate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-521-2015·2015-04-29

    Amphotericin B Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling Amphotericin B active pharmaceutical ingredient due to potential cross contamination with penicillin during repackaging.

    Product
    Amphotericin B active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-916-2015·2015-04-29

    Attix Pharmaceuticals Recalls Tegaserod Maleate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Tegaserod Maleate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Tegaserod Maleate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-658-2015·2015-04-29

    Attix Pharmaceuticals Recalls Estrone API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Estrone active pharmaceutical ingredient because it was repackaged in a facility with penicillin products without adequate separation, creating a cross-contamination risk.

    Product
    Estrone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-821-2015·2015-04-29

    Attix Pharmaceuticals Recalls Ofloxacin Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Ofloxacin active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Ofloxacin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-813-2015·2015-04-29

    Attix Pharmaceuticals Recalls Naproxen Sodium Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Naproxen Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Naproxen Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-627-2015·2015-04-29

    Attix Pharmaceuticals Recalls Dexrazoxane Due to Penicillin Cross Contamination Risk

    Attix Pharmaceuticals is recalling Dexrazoxane active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Dexrazoxane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-925-2015·2015-04-29

    Attix Pharmaceuticals Recalls Theophylline Anhydrous Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Theophylline Anhydrous active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Theophylline Anhydrous active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-791-2015·2015-04-29

    Attix Pharmaceuticals Recalls Methylprednisolone Acetate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Methylprednisolone Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Methylprednisolone Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-854-2015·2015-04-29

    Attix Pharmaceuticals Recalls Prazosin HCl Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Prazosin HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Prazosin HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-953-2015·2015-04-29

    Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-649-2015·2015-04-29

    Attix Pharmaceuticals Recalls Enzalutamide API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling enzalutamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Enzalutamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-493-2015·2015-04-29

    Attix Pharmaceuticals Recalls 2-Deoxy-D-Glucose Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling 2-Deoxy-D-Glucose active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    2-Deoxy-D-Glucose active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, On
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-642-2015·2015-04-29

    Attix Pharmaceuticals Recalls Doxycycline Hyclate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Doxycycline Hyclate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Doxycycline Hyclate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-710-2015·2015-04-29

    Attix Pharmaceuticals Recalls Hyaluronic Acid Sodium Salt Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Hyaluronic Acid Sodium Salt (Pharma Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-800-2015·2015-04-29

    Attix Pharmaceuticals Recalls Minoxidil API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Minoxidil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Minoxidil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-867-2015·2015-04-29

    Progesterone API Recalled for Potential Penicillin Cross Contamination

    Attix Pharmaceuticals is recalling progesterone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.

    Product
    Progesterone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-882-2015·2015-04-29

    Attix Pharmaceuticals Recalls Rivaroxaban API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Rivaroxaban active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Rivaroxaban active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-518-2015·2015-04-29

    Attix Pharmaceuticals Recalls Amlodipine Besylate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling amlodipine besylate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Amlodipine besylate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-582-2015·2015-04-29

    Cholestyramine API Recalled for Potential Penicillin Cross-Contamination

    Attix Pharmaceuticals is recalling Cholestyramine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Cholestyramine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-848-2015·2015-04-29

    Attix Pharmaceuticals Recalls Polidocanol Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Polidocanol (Industrial Grade) active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Polidocanol (Industrial Grade) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-579-2015·2015-04-29

    Attix Pharmaceuticals Recalls Chloroquine Phosphate Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Chloroquine Phosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Chloroquine Phosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide
  • HighFDA (Drugs)·D-522-2015·2015-04-29

    Attix Pharmaceuticals Recalls Anastrozole API Due to Penicillin Cross-Contamination Risk

    Attix Pharmaceuticals is recalling Anastrozole active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.

    Product
    Anastrozole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
    Category
    Drug
    Distribution
    Distributed nationwide